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Despite  signiﬁcant  economic  losses  resulting  from  infection  with  Anaplasma  marginale,  a  tick-transmitted
rickettsial  pathogen  of cattle,  available  vaccines  provide,  at best,  only  partial  protection  against  clinical
disease.  The  green-ﬂuorescent  protein  expressing  mutant  of the  A. marginale  St.  Maries  strain  is  a  live,
marked  vaccine  candidate  (AmStM-GFP).  To test  whether  AmStM-GFP  is safe  and  provides  clinical  protec-
tion, a group  of  calves  was  vaccinated,  and clinical  parameters,  including  percent  parasitized  erythrocytes
(PPE),  packed  cell  volume  (PCV)  and  days  required  to  reach  peak  bacteremia,  were  measured  followingovine
ick-borne disease
inoculation  and  following  tick  challenge  with  wild  type  St. Maries  strain  (AmStM).  These  clinical  parame-
ters  were  compared  to those  obtained  during  infection  with  the  A. marginale  subsp.  centrale  vaccine  strain
(A. centrale)  or wild  type  AmStM.  AmStM-GFP  resulted  in  similar  clinical  parameters  to A. centrale,  but
had a  lower  maximum  PPE,  smaller  drop  in PCV  and  took  longer  to  reach  peak  bacteremia  than  wild  type
AmStM. AmStM-GFP  provided  clinical  protection,  yielding  a stable  PCV and  low  bacteremia  following
challenge,  whereas  A.  centrale  only  afforded  partial  clinical  protection.. Introduction
Anaplasma marginale is a tick-transmitted rickettsial pathogen
f cattle resulting in decreased production due to weight loss, abor-
ion, lower milk yields and death in up to 36% of clinical cases
1]. Despite far-reaching economic impacts there is no vaccine
niversally accepted as safe and efﬁcacious. Various vaccine strate-
ies based on the immunogenic outer membrane proteins of A.
arginale sensu stricto strains have been examined. Blood-derived
hole outer membrane (OM) preparations and cross-linked surface
roteins provide the best protection from high level bacteremia and
nemia, but may  not be practical for large scale production [2–4].
Abbreviations: AmStM, Anaplasma marginale St. Maries strain; AmStM-GFP, GFP-
ransformed AmStM; OM,  outer membrane.
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Recombinant proteins, DNA vaccines and killed preparations of
A. marginale,  including inactivated cell-culture derived organisms,
have failed to recapitulate the protection seen with OM based vac-
cines [5–10]. Vaccine induced protection is complex and requires
more than antibodies to immunodominant proteins, as studies
have repeatedly demonstrated speciﬁc seroconversion in the face of
failure of clinical protection [5,10,11]. Advantages offered by a live
vaccine include a full complement of surface antigens in their native
conformations, and presentation of new surface protein variants
over time.
The A. marginale ssp. centrale (A. centrale) strain has been used
for over a century as a live vaccine against anaplasmosis, and
is now widely utilized in Australia, Israel, South Africa and sev-
eral South American countries to decrease clinical signs associated
with exposure to ﬁeld strains of A. marginale.  Because the A. cen-
trale vaccine is blood-based, it is not approved in the United
States or European Union due to the inherent risk of transmis-
sion of known or emerging blood-borne pathogens along with the
vaccine, as previously demonstrated in a batch of vaccine con-
taminated with bovine leucosis virus [12]. A. centrale protects
Open access under CC BY license. vaccinates from severe clinical disease upon challenge with ﬁeld
strains of A. marginale,  with animals generally showing mild signs
of anaplasmosis post-vaccination and post-challenge [13,14]. How-
ever, variability in clinical manifestations of anaplasmosis upon
3618 G.K. Hammac et al. / Vaccine 31 (2013) 3617– 3622
0
10
20
30
40
0
5
10
15
0 20 40 60 80
35277
0
10
20
30
40
0
5
10
15
0 20 40 60 80
35340
0
10
20
30
40
0
5
10
15
0 20 40 60 80
35349
0
10
20
30
40
0
5
10
15
0 20 40 60 80
35352
0
10
20
30
40
0
5
10
15
0 20 40 60 80
35369
AmStM-GFP
0
10
20
30
40
0
5
10
15
0 20 40 60 80
1302
0
10
20
30
40
0
5
10
15
0 20 40 60 80
6171
0
10
20
30
40
0
5
10
15
0 20 40 60 80
6175
0
10
20
30
40
0
5
10
15
0 20 40 60 80
6187
0
10
20
30
40
0
5
10
15
0 20 40 60 80
6188
A. cen trale
0
10
20
30
40
0
5
10
15
0 20 40 60 80
951
0
10
20
30
40
0
5
10
15
0 20 40 60 80
956
0
10
20
30
40
0
5
10
15
0 20 40 60 80
1200
0
10
20
30
40
0
5
10
15
0 20 40 60 80
31794
0
10
20
30
40
0
5
10
15
0 20 40 60 80
31919
AmStM
P
P
E
P
C
V
Days po st-infection
A. B. C.
Fig. 1. PPEs and PCVs of AmStM-GFP needle-inoculated (A) (n = 5), A. centrale needle-inoculated (B) (n = 5), and AmStM tick transmitted calves (C) (n = 14; 5 represented)
during  acute anaplasmosis. Animal identiﬁcation numbers are indicated on each panel. Bacteremia (left axis, ) is reported as percent parasitized erythrocytes as determined
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ay  0 is the day of needle inoculation (A and B) or the day of tick application (C). Ax
nfection with the vaccine strain and protection from clinical signs
pon challenge with ﬁeld strains is well documented. Studies in
ustralia, South Africa, Kenya and Argentina generally demon-
trated mild clinical signs post-vaccination and protection against
evere disease upon challenge with A. marginale,  whereas studies
n Zimbabwe, Paraguay and Argentina have shown that the same
. centrale strain provides little to no protection [15–19]. Poten-
ial explanations for variable efﬁcacy include dissimilar endemic
trains by country and variation in the challenge dose among
tudies.Cross-protection provided by A. centrale against challenge with
eld strains of A. marginale is attributed to conserved epitopes
20–22], however there is a much lower degree of conservation
etween the deduced amino acid sequences of surface proteinso evaluate anemia during infection. The x-axis indicates days post-infection where
ues have been standardized to allow comparison between graphs.
of A. centrale and sequenced A. marginale strains than between
any two A. marginale strains examined to date. The greater diver-
gence between A. centrale and A. marginale ﬁeld strains has been
demonstrated in molecular studies: a multi-strain sequencing
approach to identify conserved vaccine candidates identiﬁed 19
expressed genes with >90% identity among 10 U.S. strains of A.
marginale. While these sequences all had homologs in A. centrale,
they were conserved to a much lesser degree, typically between
60% and 80% [23,24]. Additional sequence comparisons revealed
more divergence among surface proteins between A. centrale and A.
marginale than when comparing just between A. marginale strains:
72.4% versus 95.1% average identity [22]. In contrast, housekeep-
ing proteins had higher identities: 97.3% identity when comparing
between A. centrale and A. marginale and 99.7% identity among A.
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Fig. 2. Clinical parameters of groups of naïve calves needle inoculated with AmStM-
GFP (n = 5), A. centrale (Ac) (n = 5) or infected by tick transmission of AmStM (n = 14).
The  group mean is represented by a gray bar, with error bars depicting the standard
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tube centrifugation to determine packed cell volume (PCV) as arror. Bars with arrows indicate the range of values for each group. Statistical sig-
iﬁcance is indicated by an asterisk (*).
arginale strains [22]. These data suggest that better protection
ay  be afforded by a vaccine strain with greater identity to ﬁeld
trains of A. marginale.
Here we examine whether a transformed and cell culture-
erived A. marginale St. Maries strain, more closely related to North
merican ﬁeld strains of A. marginale,  is an alternative approach for
afe and effective vaccination. The green ﬂuorescent protein (GFP)-
xpressing mutant of A. marginale St. Maries strain (AmStM-GFP)
as created by transposon mediated insertion of a 4.5 kb construct
ontaining antibiotic resistance genes for selection and Turbo GFP
s a marker, and grows more slowly than the parent strain in
ulture [25,26]. The stability of the insert has been demonstrated
hrough a complete in vivo transmission cycle [27]. Two advantages
f AmStM-GFP as a vaccine compared to A. centrale are its potential
o provide better protection due to greater similarity to ﬁeld strains,
nd elimination of the risk of delivering emerging pathogens as it
s maintained in deﬁned medium in cell culture. In this study we
nvestigate AmStM-GFP as a live, cell culture-based vaccine can-
idate, and test the hypothesis that infection with AmStM-GFP
auses only mild clinical signs and provides clinical protection
o vaccinated calves upon challenge with a homologous ﬁeld
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2. Methods
2.1. Cattle inoculation
AmStM-GFP was maintained in ISE6 cells cultured at 34 ◦C as
previously described [25,28,29]. When passage 27 of AmStM-GFP
infected greater than 80% of ISE6 cells in a T75 cell culture ﬂask, as
determined by examination of Giemsa-stained cytospin prepara-
tions, all cells were re-suspended in 25 mL  of media. Three milliliter
aliquots of fresh, intact, unpuriﬁed cell culture suspension, each
containing 109 organisms, were injected intravenously into the
jugular vein of each of ﬁve male, age-matched, seronegative Hol-
stein calves: 35277, 35340, 35349, 35352, and 35369.
Unpublished clinical data from animal experiments in which
naïve calves were infected with either A. centrale or the St. Maries
strain of A. marginale were used in comparisons with AmStM-GFP
inoculated calves described above. Five naïve calves were injected
with A. centrale-infected stabilate, with inoculums containing 108
organisms (6171, 6175, 6187, and 6188) or 1010 organisms (1302)
[30]. A. centrale stabilates were prepared from packed erythrocytes,
previously washed 3 times in PBS, resuspended in an equal volume
of stabilate buffer (1× PBS and 31.2% DMSO), and then plunged into
liquid nitrogen. At the time of intravenous injection, 2 mL of stabi-
late were thawed and mixed with 10 mL  of Hank’s balanced salt
solution. Fourteen naïve calves (951, 956, 988, 995, 1024, 1067,
1075, 1076, 1200, 1247, 1280, 31794, 31919, and 31993) were
infected with AmStM by a 7 day tick-transmission using Derma-
centor andersoni from the Reynolds Creek stock [31].
All animals were determined to be negative for antibodies to
A. marginale by competitive ELISA (VMRD, Pullman, WA)  prior to
experimental infection [32]. Sera from vaccinated and control ani-
mals were tested by cELISA to conﬁrm seroconversion after peak
bacteremia.
2.2. AmStM challenge
A naïve calf (36676) was inoculated with AmStM stabilate, and
infection was established as evidenced by positive Giemsa-stained
blood smears and seroconversion. When animal 36676 was in
the persistent phase of infection, approximately 460 ticks were
applied for a seven day acquisition feed. Ticks were held at 26 ◦C
for seven days to allow for clearance of the blood meal from the
mouthparts, then 51 ticks were placed on each of four AmStM-
GFP infected calves seven months post-inoculation (35277, 35340,
35349, 35352; AmStM-GFP inoculated calf 35369 was  removed
from the experiment prior to challenge for unrelated health rea-
sons) and ﬁve additional naïve control calves (35294, 35338, 35356,
35370, and 35371) for a seven day transmission feed. Following
transmission, cohorts of 10 ticks per calf were conﬁrmed positive
for AmStM with levels ranging from 103 to 107 organisms per sali-
vary gland pair.
Calf 1302 was challenged intravenously with 109 AmStM blood
stabilate-derived organisms thirteen months following inoculation
with A. centrale.
2.3. Animal monitoring
Following inoculation and challenge, blood samples were col-
lected throughout the period of detectable bacteremia. Blood
samples were analyzed by microscopic examination of Giemsa-
stained blood smears to determine the level of bacteremia
expressed as percent parasitized erythrocytes (PPE) and capillarymeasure of anemia.
Animal experiments were approved by the Institutional Animal
Care and Use Committee at Washington State University, USA, in
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Fig. 3. Clinical parameters following challenge with AmStM. (A) Calves inoculated with AmStM-GFP (n = 4), (B) naïve calves (n = 5) and (C) A. centrale inoculated calf (n = 1).
Animal  identiﬁcation numbers are indicated on each panel. The x-axis indicates days post-challenge where day 0 is the day of tick application (A and B) or needle challenge
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wC).  Bacteremia (left axis, ) is reported as percent parasitized erythrocytes as deter
sed  to evaluate anemia during infection. Axes values have been standardized to a
nd  35371 in B, which were altered to accommodate higher PPE values.
ccordance with institutional guidelines based on the U.S. National
nstitutes of Health (NIH) Guide for the Care and Use of Laboratory
nimals.
.4. Quantitative PCRTo determine the dose of AmStM-GFP in the inoculum and
nfection levels in the ticks used for transmission, genomic DNA
as extracted from cell culture suspension and tick salivary glands by microscopic evaluation of Giemsa-stained blood smears. PCV (right axis, ) was
omparison between graphs, with the exception of the left y-axis for 35338, 35356
post-transmission using the Puregene DNA Puriﬁcation cell kit
(Qiagen). Quantitative real time PCR of msp5, a conserved single-
copy gene, was  performed with SybrGreen (Invitrogen), and
used to determine the number of organisms in each sample. For
quantitative ampliﬁcation, forward 5′-ATA CCT GCC TTT CCC ATT
GAT GAG GTA CAT-3′ and reverse 5′-AGG CGA  AGA AGC AGA
CAT AAA GAG CGT-3′ primers were used. Standard curves were
constructed by ampliﬁcation of a serial dilution of msp5 cloned
into PCR4-Topo (Invitrogen), and ampliﬁed simultaneously with
accine 31 (2013) 3617– 3622 3621
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Fig. 4. Southern analysis of gfp positive animals during persistent infection. South-
ern blot following nested PCR targeting gfp in genomic DNA extracted from calfG.K. Hammac et al. / V
enomic DNA samples. Ampliﬁcation consisted of an initial 2 min
t 50 ◦C and 10 min  at 95 ◦C, followed by 45 cycles of melting at
5 ◦C for 15 s, and annealing and extension at 60 ◦C for 1 min, and
 ﬁnal extension at 72 ◦C for 7 min.
.5. Southern analysis
To detect the presence of AmStM-GFP in vaccinated animals
uring persistent infection (7 months post inoculation) when the
rganism is undetectable in blood smears, nested PCR followed by
outhern blot targeting gfp was performed. Reaction A of the nested
CR was performed with the following primers: GFP F (ATG GAG
TC GAG TGC CGC A) and GFP R (CGG TGT TGC TGT GAT CCT CCT).
FP F2 (ATG ACC AAC AAG ATG AAG AGC ACC A) and GFP R2 (CCG
CC TCG TAC TTC TCG) were used for reaction B of nested PCR and
or production of the digoxigenin-labeled probe using the PCR DIG
robe synthesis kit (Roche). Ampliﬁcation for reaction A consisted
f thirty ﬁve cycles of denaturing at 95 ◦C for 15 s, annealing at
0 ◦C for 15 s and extension at 72 ◦C for 30 s, followed by a 7 min
xtension at 72 ◦C and holding at 4 ◦C. Reaction B differed with
 lower annealing temperature of 58.5 ◦C and reduced extension
ime of 15 s. The Southern blot was performed according to the DIG
pplication manual (Roche).
.6. Statistics
For days to peak and minimum PCV, mean differences were
ompared between groups using ANOVA for overall differences
etween the groups and pairwise comparisons controlling for mul-
iple comparisons using Tukey’s test. Because maximum PPE was
ot normally distributed, median values were compared using
he Kruskal–Wallis procedure controlling for multiple comparisons
sing the Bonferroni–Dunn procedure in WinPepi software [33].
. Results and discussion
To determine safety of AmStM-GFP as a vaccine, clinical parame-
ers were compared between animals inoculated with AmStM-GFP
ersus AmStM or A. centrale. When comparing animals inoc-
lated with cultured AmStM-GFP with those inoculated with
on-cultured AmStM, all measured clinical parameters were sig-
iﬁcantly different. Infection with AmStM-GFP resulted in a lower
eak PPE, a smaller drop in PCV, and took longer to reach peak
PE as compared to AmStM (Fig. 1A and C). The bacteremia lev-
ls measured as PPE were higher in AmStM infected animals than
n AmStM-GFP infected animals with non-overlapping ranges of
.1–14.8% and 0.52–1.7%, respectively (p < 0.01) (Fig. 2A). Anemia
s measured by PCV was less severe in AmStM-GFP inoculated ani-
als than in AmStM inoculated animals (p < 0.01) (Fig. 2B). The
ime required to reach peak infection was longer for AmStM-GFP
han AmStM with non-overlapping ranges of 41–50 days and 22–37
ays, respectively (p < 0.01) (Fig. 2C). Our data is consistent with
reviously reported data that AmStM-GFP grows more slowly than
he parent strain in culture, and takes longer to reach peak bac-
eremia in the bovine host [25,27]. At no point in the 10-month
xperiment did any animals experience a reversion to virulence of
mStM-GFP.
When comparing between naïve animals needle inoculated
ith AmStM-GFP or A. centrale stabilate, only one of three clinical
arameters was signiﬁcantly different. AmStM-GFP infected cattle
ook longer to achieve peak bacteremia than those infected with
. centrale (41–50 days vs. 34–46 days) (p < 0.01) (Fig. 2C). The
aximum PPEs and minimum PCVs between groups were not
igniﬁcantly different (Fig. 2A and B), and the infection proﬁles
ere similar (Fig. 1A and B). The post-vaccination infection proﬁlesblood seven months post-vaccination: (+) positive plasmid control, (−) negative
water control, (M)  DNA Molecular Weight Marker VIII, DIG-labeled (Roche), (1) calf
#35277, (2) calf #35340, (3) calf #35349, and (4) calf #35352.
indicate that AmStM-GFP results in similar levels of bacteremia
and anemia as the A. centrale vaccine strain.
Following tick challenge of four AmStM-GFP inoculated animals
with wild type AmStM, PCV and PPE were monitored for evi-
dence of transmission to assess protection. PCV ﬂuctuated within
the normal range from 26 to 36 throughout 90 days of monitor-
ing (Fig. 3A). Six individual blood smears, representing all four
challenged calves at various time points from day 22 to day 52
post-challenge, were positive with calculated PPEs ranging from
0.006% to 0.03%. These positive blood smears were preceded and
followed by negative smears on adjacent days and did not cor-
respond to a decrease in PCV. These results are contrasted with
those obtained after vaccination with A. centrale both in this study
(Fig. 3C) and in previously published studies [13,30], where a char-
acteristic peak of bacteremia associated with a drop in PCV is
seen after challenge with A. marginale.  The A. centrale vaccinated
animal had measurable bacteremia and associated mild anemia fol-
lowing challenge with AmStM, in contrast to the near absence of
microscopically detectable bacteremia observed in the AmStM-GFP
vaccinated group (Fig. 3A and C). That A. centrale vaccinated animals
become infected with the challenge strain, but are protected from
high infection levels and severe anemia has been shown repeat-
edly [13,18]. The ﬁve control calves were successfully infected by
tick challenge as evidenced by seroconversion and development of
the expected infection proﬁles (Fig. 3B). The presence of the vac-
cine strain was  conﬁrmed by molecular methods in all four calves
seven months post-vaccination, despite the absence of detectable
parasitemia by Giemsa-stained blood smears (Fig. 4).
4. Conclusions
This study describes a live, culture-based vaccine for anaplas-
mosis using a marked strain of A. marginale.  Several features of this
potential vaccine are noteworthy: (1) cell culture-based vaccines
eliminate the risk of pathogen transmission; (2) transformation of
AmStM has produced a stable, marked, slower growing strain that
can be distinguished from ﬁeld strains (AmStM-GFP was  detectable
in all four vaccinated calves with negative blood smears seven
months post-infection) [25,27]; (3) because of the persistent nature
of A. marginale infection, only a single dose of live AmStM-GFP is
required for protection [27]; and (4) the ﬁndings of this study indi-
cate that AmStM-GFP provides protection against disease following
homologous challenge. Further trials are warranted to determine
if protection is extended to heterologous challenge. A drawback
of this potential vaccine is that it carries an antibiotic resistance
marker, but this could be replaced by an inconsequential marker
in future trials. These initial studies are a proof of concept for the
basis of future development for this type of vaccine.
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